{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-030776","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.106669+00:00","generated_at":"2026-06-04T22:22:07.173447+00:00","sec_items":["2.02","9.01","2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spruce Biosciences reports CAHmelia-203 fails primary endpoint; cuts 21% workforce","bullets":["CAHmelia-203 failed primary endpoint; tildacerfont 200mg QD showed -2.6% placebo-adjusted A4 reduction (non-significant).","Board approved workforce reduction of ~21% and termination of CAHmelia-203; estimated $0.4M cash charges, Q2 2024.","Pediatric CAHptain-205: 73% of patients met A4 or GC reduction endpoint; more rapid clearance than adults.","Cash and equivalents $96.3M at Dec 31, 2023; cost reductions extend runway through end of 2025.","Expects topline CAHmelia-204 in Q3 2024, additional CAHptain-205 data in Q4 2024, FDA meeting in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-030776","json":"https://secwatch.observer/filing/0000950170-24-030776.json","markdown":"https://secwatch.observer/filing/0000950170-24-030776.md","text":"https://secwatch.observer/filing/0000950170-24-030776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/sprb-20240310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:22:07.173447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99d45e19caa5084cc61bd3d2b6d083e81fdd8ea2","claim":"SPRUCE BIOSCIENCES, INC. reported full year ended December 31, 2023 results: revenue $10.1 million, net income $47.9 million.","evidence_excerpt":"topline results from CAHmelia-204 and additional dose-ranging data from CAHptain-205. • Collaboration Revenue: Collaboration revenue for the year ended December 31, 2023 was $10.1 million compared to nil in 2022, reflecting the partial recognition of the $15.0 million upfront payment received from Kaken Pharmaceutical (“Kaken”) in connection with the company’s","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Revenue","value":"$10.1 million"},{"label":"Net income","value":"$47.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a49299b11be53df0046bf3545e7057eaa8df6285","claim":"SPRUCE BIOSCIENCES, INC. announced a restructuring with charges of the Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to e affecting workforce reduction of approximately 21% (workforce reduction of approximately 21%).","evidence_excerpt":"and expenditures relating to the Realignment Plan will not be known until all related activities have been completed. The Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to employee severance payments and healthcare coverage assistance and related costs. The","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"the Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to e"},{"label":"Affected area","value":"workforce reduction of approximately 21%"},{"label":"Headcount","value":"workforce reduction of approximately 21%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}